Updated December 2025

At Belite Medical Center, we understand that sustainable weight loss is not just about discipline—it’s about biology. Hormones, genetics, appetite signaling, sleep, stress, and metabolism all play a role in body weight. For many patients, lifestyle strategies alone aren’t enough, and that’s where today’s weight-loss medications can be transformative.

Modern anti-obesity medications are safe when prescribed and monitored by licensed clinical practitioners, well-studied, and—most importantly—effective when paired with appropriate diet and exercise. The goal of this blog post is to review the most powerful treatments available today, including GLP-1 medications, dual and triple agonists, and phentermine, with verified evidence from high-quality clinical trials.

Why Medications Matter in Weight Loss

Obesity is now recognized as a chronic, relapsing medical condition, not a character flaw. Medications can help regulate appetite, decrease cravings, stabilize blood sugar, reduce “food noise,” and support behavior change—making long-term weight loss more achievable. Reflecting the chronic nature of obesity, newer weight loss medications are FDA approved for long-term weight management.

Studies show that adding anti-obesity medication to lifestyle interventions can double or triple typical weight-loss outcomes. These medications can also improve diabetes risk, reduce blood pressure, improve overall metabolic health, reduce various health risks associated with obesity, and improve psychological well-being.

GLP-1 & Incretin-Based Therapies: The Modern Weight-Loss Breakthrough

Semaglutide (Wegovy)

One of the most effective non-surgical weight-loss treatments available today. Medication is administered as once-per-week subcutaneous injections. The dose is increased as tolerated to a maximum dose of 2.4 mg.

Key Clinical Evidence:

• STEP-1 Trial: –14.9% average weight loss at 68 weeks vs –2.4% with placebo. (PubMed: 33567185)
• SELECT Trial (Cardiovascular Outcomes): In patients with cardiovascular disease and overweight/obesity but without diabetes, semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% compared to placebo. This led to FDA approval for cardiovascular risk reduction—the first weight-loss medication approved for this indication. (PubMed: 37952131)
• Typical effectiveness: 15% total body weight loss over the duration of clinical trials.
• Common side effects: nausea, vomiting, diarrhea/constipation, abdominal discomfort, reflux.

Pricing Update: As of late 2025, patients without insurance should check goodrx.com and Novo Nordisk for reduced prices. The TrumpRx platform is scheduled to go live in January 2026, with a reported price of $350/month.

Tirzepatide (Zepbound)

Tirzepatide is a dual GIP and GLP-1 receptor agonist, representing a significant advancement in obesity treatment. Medication is administered as once-per-week subcutaneous injections.

Key Clinical Evidence:

• SURMOUNT-1 Trial: Patients achieved 20–22% weight loss at higher doses (12.5 mg or 15 mg). (PubMed: 35658024)
• Direct comparison studies show tirzepatide is more effective on average than semaglutide for weight loss.
• Typical effectiveness: 18–22% total body weight loss over 72 weeks.

Important Note for Women: The manufacturer of Zepbound recommends that females use non-oral contraceptive methods or add barrier contraception for 4 weeks after starting tirzepatide and after each dose increase. This differs from other GLP-1 agonists like semaglutide and liraglutide, which do not appear to affect the efficacy of oral contraceptives.

Pricing Update: As of late 2025, patients without insurance should check goodrx.com and Novo Nordisk for reduced prices. The TrumpRx platform is scheduled to go live in January 2026, with a reported price of $350/month..

A direct comparison of semaglutide versus tirzepatide showed that on average tirzepatide is more effective, as per our recent blog post: Tirzepatide vs. Semaglutide: Which Weight Loss Drug Works Better?

Liraglutide (Saxenda) – Now Available as Generic

Liraglutide 3.0 mg remains an effective option for weight management, and importantly, a generic version is now available, making it more accessible and affordable. This is the first generic GLP-1 medication specifically indicated for weight loss.

Key Clinical Evidence:

• SCALE Trial: Approximately 8% weight loss over 56 weeks. 63.2% of patients lost at least 5% of their body weight (vs. 27.1% placebo); 33.1% lost more than 10% (vs. 10.6% placebo). (PubMed: 26132939)

Generic Availability: Teva Pharmaceuticals launched the first generic liraglutide for weight loss in 2025, priced approximately 30% less than brand-name Saxenda. This is an excellent option for patients who need a more affordable GLP-1 option.

Emerging & Next-Generation Therapies

The obesity treatment landscape continues to evolve rapidly. Several promising medications are in late-stage development or awaiting FDA approval.

CagriSema (Semaglutide + Cagrilintide) – FDA Filing December 2025

CagriSema is a once-weekly combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (an amylin analog). By targeting two different appetite-regulating pathways, CagriSema offers enhanced weight loss compared to either component alone.

Key Clinical Evidence:

• REDEFINE 1 Trial: 4% mean weight reduction at 68 weeks in adults with obesity/overweight without diabetes,  compared to 11.5% with cagrilintide, 14.9% with semaglutide, and 3% with placebo. 40.4% achieved at least 25% weight loss when adhering to treatment. (PubMed: 40544433)
• REDEFINE 2 Trial: 7% mean weight reduction in patients with type 2 diabetes and obesity. (PubMed: 40544432)

Status: Novo Nordisk filed for FDA approval in December 2025. If approved, CagriSema would be the first once-weekly combination of GLP-1 and amylin analogues for weight management.

Retatrutide – Triple Agonist (In Phase 3 Trials)

Retatrutide is a first-in-class triple hormone receptor agonist that targets GIP, GLP-1, AND glucagon receptors simultaneously. This represents the next chapter in obesity pharmacotherapy.

Key Clinical Evidence:

• Phase 2 Trial: “At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of those who received placebo.” (NEJM: 10.1056/NEJMoa2301972)
• TRIUMPH-4 Phase 3 Trial (December 2025): Up to 23.7% weight loss (approximately 60 lbs average) at 68 weeks, plus significant pain reduction in patients with knee osteoarthritis. Blood pressure reduction of up to 14 mmHg systolic observed. Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial.

Status: Multiple Phase 3 trials (TRIUMPH program) are ongoing. Eli Lilly is expected to seek FDA approval pending completion of the trial program in 2026.

Oral GLP-1 Pills – Coming Soon

For patients who prefer pills over injections, exciting developments are underway:

Oral Semaglutide 25 mg (Novo Nordisk):

• OASIS 4 Trial: 6% weight loss over 64 weeks—comparable to injectable Wegovy. (PubMed: 40934115)
• Expected to be approved soon; FDA filing completed.

Orforglipron (Eli Lilly):

• A novel non-peptide oral GLP-1 with 12.4% average weight loss at 72 weeks.
• No food or water restrictions (unlike oral semaglutide), making it more convenient.
• FDA filing expected soon with priority review.

Phentermine & Oral Options

Phentermine

Phentermine has been used since 1959 and remains one of the most widely prescribed appetite suppressants.

Key Clinical Evidence:

• Long-term Safety Study: In a large cohort (>13,000 adults), long-term phentermine use produced significant weight loss with no increase in cardiovascular events in low-risk individuals. (PubMed: 30900410)
• Typical effect: 5–10% weight loss over 3–12 months.

Phentermine is an excellent option for patients who: cannot access or tolerate GLP-1s; prefer oral medication; need a cost-effective option; or have no uncontrolled cardiovascular issues.

Side effects may include insomnia, dry mouth, increased heart rate, elevated blood pressure, and anxiety.

For more information, check our website: Weight Loss Medications Fairfax, VA

Readers might be interested in some of our Medical Director’s publications on phentermine: PubMed Search: Rothman RB AND Phentermine

Phentermine/Topiramate ER (Qsymia)

This combination medication offers enhanced weight loss compared to phentermine alone.

Key Clinical Evidence:

• CONQUER Trial: 10–11% weight loss at 56 weeks. (PubMed: 21481449)
• Topiramate (Brand Name Topamax) is also FDA approved for migraine prevention and is often prescribed as a separate pill along with phentermine as an augmenting agent.

Important: Requires reliable contraception due to topiramate’s teratogenic effects.

Other FDA-Approved Medications

Naltrexone/Bupropion (Contrave)

This combination targets the brain’s reward and appetite centers.

Key Clinical Evidence:

• COR-I Trial: 6–8% weight loss vs approximately 2% with placebo. (PubMed: 20673995)
• May be particularly helpful for patients with food cravings related to emotional eating.

Orlistat (Xenical/Alli)

This medication works by blocking fat absorption in the gut. Alli is available over-the-counter at a lower dose.

Key Clinical Evidence:

• XENDOS Study: Modest weight loss plus reduced diabetes risk. (PubMed: 14693982)

Setmelanotide (Imcivree)

This FDA-approved medication is specifically for patients with obesity due to certain rare genetic conditions (such as POMC, PCSK1, or LEPR deficiency). (PubMed: 33137293)

Important Considerations

Safety Information

GLP-1 medications carry a boxed warning about the risk of thyroid C-cell tumors (observed in rodent studies). They should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Dual agonists like tirzepatide may interfere with hormonal birth control. Always discuss contraception options with your provider.

Choosing the Right Medication for You

So… what medication is best for you? This critical question should be discussed with your medical provider. Several factors influence the decision:

• Insurance coverage: With GLP-1s, coverage is an important issue. Without insurance with reasonable co-pays, these medications may not be affordable for most people. The new lower direct-to-consumer prices ($299–$349/month) and upcoming oral versions ($149/month) may improve accessibility.
• Injection vs. oral preference: Phentermine and similar oral medications might be the only option for people who don’t like injections. Oral GLP-1 pills are coming soon for those who want GLP-1 benefits without injections.
• Cost considerations: Generic liraglutide (generic Saxenda) now offers a more affordable GLP-1 option. Phentermine remains the most cost-effective choice.
• Medical history: Cardiovascular disease, diabetes status, thyroid conditions, and other factors all influence medication choice.
• Weight loss goals: For those needing more substantial weight loss, tirzepatide or the upcoming retatrutide may offer advantages.

The obesity treatment landscape has never been more promising. With continued innovation and improving accessibility, effective weight management is becoming achievable for more patients than ever before.

How BeLite Can Help

At BeLite Medical Center, we understand that successful weight loss is a multifaceted journey. Our comprehensive approach combines weight loss medications, personalized exercise plans, and healthy diet strategies. If you’ve been struggling to reach your weight goals, our expert team is here to guide you.

Booking appointments is simple with our online portal available 24/7 at BELITE MEDICAL CENTER | Scheduling and Booking Website. You can also call or text us at (703) 359‑9200, or email belitemed@gmail.com. We offer free consultations for new patients. If you choose not to enroll, there is no charge. We serve patients across Virginia, Maryland, Washington D.C., the DMV area, Pennsylvania, and West Virginia. Patients do not sign treatment contracts and can stop coming at any time.

 

Disclaimer

Medical Disclaimer: This blog post is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not intended to substitute for consultation with a licensed healthcare provider. Readers should not use this information to diagnose or treat a medical or health condition without consulting an appropriately qualified healthcare professional. Any reliance on the information in this blog is at the reader’s own risk. Individual weight loss results vary based on personal health status and adherence to medical advice. No doctor-patient relationship is created by accessing or reading this content.